antofloxacin

antibiotic; 8-amino derivative of levofloxacin; structure in first source

Also Known As:

antofloxacin hydrochloride; 7H-1,4-Oxazino(2,3,4-ij)quinoline-6-carboxylic acid, 8-amino-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-, (3S)-

Networked: 11 relevant articles (2 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Quinolines: 146
      - Quinolones: 2938
        Fluoroquinolones: 5348
        Ofloxacin: 1826
        antofloxacin: 11

Experts

1.	Liao, Xiao-Ping: 3 articles (11/2020 - 01/2017)
2.	Liu, Ya-Hong: 3 articles (11/2020 - 01/2017)
3.	Sun, Jian: 3 articles (11/2020 - 01/2017)
4.	Zhou, Yu-Feng: 3 articles (11/2020 - 01/2017)
5.	Tao, Meng-Ting: 2 articles (01/2018 - 01/2017)
6.	Xiao, Yong-hong: 2 articles (03/2011 - 10/2008)
7.	He, Xiao-Jian: 1 article (03/2021)
8.	Jiang, Chuan-Shen: 1 article (03/2021)
9.	Li, Da-Zhou: 1 article (03/2021)
10.	Liu, Gang: 1 article (03/2021)

Related Diseases

1.	Bacterial Infections (Bacterial Infection) 11/01/2012 - "The ratio of AUC from the PPK model vs MIC as the PD parameter can be applied in a dose-finding trial of antofloxacin in treatment of bacterial infections. " 11/01/2012 - "Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers." 03/01/2011 - "Antofloxacin hydrochloride tablet was effective and safe for the treatment of acute bacterial infections." 01/01/2010 - "A phase II study of antofloxacin hydrochloride, a novel fluoroquinolone, for the treatment of acute bacterial infections." 03/01/2011 - "To evaluate the clinical efficacy and safety of antofloxacin hydrochloride tablet for the treatment of acute bacterial infections. "
2.	Infections 01/01/2018 - "In Vivo Bioluminescent Monitoring of Therapeutic Efficacy and Pharmacodynamic Target Assessment of Antofloxacin against Escherichia coli in a Neutropenic Murine Thigh Infection Model." 01/01/2018 - "Following thigh infection, the mice were treated with 2-fold-increasing doses of antofloxacin from 2.5 to 80 mg/kg administered every 12 h. " 01/01/2017 - "We explored the pharmacodynamic (PD) profile and targets of antofloxacin against seven Klebsiella pneumoniae isolates by using a neutropenic murine lung infection model. " 01/01/2017 - "In Vivo Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin against Klebsiella pneumoniae in a Neutropenic Murine Lung Infection Model." 10/01/2008 - "Using the neutropenic murine thigh infection model, we defined the pharmacodynamic profile and property of antofloxacin hydrochloride against Staphylococcus aureus. "
3.	Phototoxic Dermatitis (Phototoxicity) 02/01/2016 - "Effect of C-5 position on the photochemical properties and phototoxicity of antofloxacin and levofloxacin: A stable and transient study."
4.	Chronic Bronchitis 01/01/2010 - "To evaluate the clinical and bacterial efficacies and the safety of antofloxacin hydrochloride tablets in the treatment of acute exacerbations of chronic bronchitis (AECB) and acute pyelonephritis (AP). "
5.	Staphylococcal Infections 10/01/2008 - "Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection."

Related Drugs and Biologics

1.	Tablets
2.	Levofloxacin (Levaquin)
3.	Fluoroquinolones
4.	Bismuth
5.	Pectins
6.	Amoxicillin (Wymox)
7.	Lansoprazole (Prevacid)
8.	Esomeprazole (Nexium)
9.	Clarithromycin (Biaxin)

Related Therapies and Procedures

1.	Therapeutics